Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.

Li J, Kankam M, Trone D, Gammon G.

Br J Clin Pharmacol. 2019 Jun 7. doi: 10.1111/bcp.14022. [Epub ahead of print]

PMID:
31173645
2.

Association Between Dietary Supplement Use and ICD-9-CM Code Classification in Active Duty US Navy and Marine Corps Service Members.

Humphreys MA, Phillips CJ, Trone DW.

Mil Med. 2019 Apr 2. pii: usz053. doi: 10.1093/milmed/usz053. [Epub ahead of print]

PMID:
30938810
3.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ.

Cancer Discov. 2019 Mar;9(3):384-395. doi: 10.1158/2159-8290.CD-18-0839. Epub 2018 Nov 28.

PMID:
30487236
4.

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.

Papadopoulos KP, Ben-Ami E, Patnaik A, Trone D, Li J, Demetri GD.

BMC Cancer. 2018 Aug 6;18(1):790. doi: 10.1186/s12885-018-4692-z.

5.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

6.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
7.

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.

Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS.

Am J Hematol. 2018 Feb;93(2):213-221. doi: 10.1002/ajh.24974. Epub 2017 Dec 4.

8.

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.

Sandmaier BM, Khaled S, Oran B, Gammon G, Trone D, Frankfurt O.

Am J Hematol. 2018 Feb;93(2):222-231. doi: 10.1002/ajh.24959. Epub 2017 Nov 17.

9.

Smoking and drinking behaviors of military spouses: Findings from the Millennium Cohort Family Study.

Trone DW, Powell TM, Bauer LM, Seelig AD, Peterson AV, Littman AJ, Williams EC, Maynard CC, Bricker JB, Boyko EJ.

Addict Behav. 2018 Feb;77:121-130. doi: 10.1016/j.addbeh.2017.09.015. Epub 2017 Sep 28.

PMID:
28992577
10.

Assessment of Initial Vancomycin Dosing in Pediatric Oncology Patients.

Orr H, Trone D, Elder J, Raj A.

Children (Basel). 2017 Aug 28;4(9). pii: E79. doi: 10.3390/children4090079.

11.

Caffeine Use among Active Duty Navy and Marine Corps Personnel.

Knapik JJ, Trone DW, McGraw S, Steelman RA, Austin KG, Lieberman HR.

Nutrients. 2016 Oct 9;8(10). pii: E620.

12.

Prevalence, Adverse Events, and Factors Associated with Dietary Supplement and Nutritional Supplement Use by US Navy and Marine Corps Personnel.

Knapik JJ, Trone DW, Austin KG, Steelman RA, Farina EK, Lieberman HR.

J Acad Nutr Diet. 2016 Sep;116(9):1423-1442. doi: 10.1016/j.jand.2016.02.015. Epub 2016 Apr 12.

13.

Sleep and Health Resilience Metrics in a Large Military Cohort.

Seelig AD, Jacobson IG, Donoho CJ, Trone DW, Crum-Cianflone NF, Balkin TJ.

Sleep. 2016 May 1;39(5):1111-20. doi: 10.5665/sleep.5766.

14.

Recent Sexual Trauma and Adverse Health and Occupational Outcomes Among U.S. Service Women.

Millegan J, Milburn EK, LeardMann CA, Street AE, Williams D, Trone DW, Crum-Cianflone NF.

J Trauma Stress. 2015 Aug;28(4):298-306. doi: 10.1002/jts.22028. Epub 2015 Jul 22.

PMID:
26201507
15.

Longitudinal Investigation of Smoking Initiation and Relapse Among Younger and Older US Military Personnel.

Boyko EJ, Trone DW, Peterson AV, Jacobson IG, Littman AJ, Maynard C, Seelig AD, Crum-Cianflone NF, Bricker JB.

Am J Public Health. 2015 Jun;105(6):1220-9. doi: 10.2105/AJPH.2014.302538. Epub 2015 Apr 16.

16.

Injury-reduction effectiveness of prescribing running shoes on the basis of foot arch height: summary of military investigations.

Knapik JJ, Trone DW, Tchandja J, Jones BH.

J Orthop Sports Phys Ther. 2014 Oct;44(10):805-12. doi: 10.2519/jospt.2014.5342. Epub 2014 Aug 25.

PMID:
25155917
17.

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators.

Br J Haematol. 2014 Nov;167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8.

18.

Self-reported smoking and musculoskeletal overuse injury among male and female U.S. Marine Corps recruits.

Trone DW, Cipriani DJ, Raman R, Wingard DL, Shaffer RA, Macera CA.

Mil Med. 2014 Jul;179(7):735-43. doi: 10.7205/MILMED-D-13-00516.

PMID:
25003858
19.

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M.

J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3.

20.

The association of self-reported measures with poor training outcomes among male and female U.S. Navy recruits.

Trone DW, Cipriani DJ, Raman R, Wingard DL, Shaffer RA, Macera CA.

Mil Med. 2013 Jan;178(1):43-9.

PMID:
23356118
21.

Injury reduction effectiveness of assigning running shoes based on plantar shape in Marine Corps basic training.

Knapik JJ, Trone DW, Swedler DI, Villasenor A, Bullock SH, Schmied E, Bockelman T, Han P, Jones BH.

Am J Sports Med. 2010 Sep;38(9):1759-67. doi: 10.1177/0363546510369548. Epub 2010 Jun 24.

PMID:
20576837
22.

Selected static anatomic measures predict overuse injuries in female recruits.

Rauh MJ, Macera CA, Trone DW, Reis JP, Shaffer RA.

Mil Med. 2010 May;175(5):329-35.

PMID:
20486504
23.

Factors associated with discharge during marine corps basic training.

Reis JP, Trone DW, Macera CA, Rauh MJ.

Mil Med. 2007 Sep;172(9):936-41.

PMID:
17937356
24.

Is radiographic vertebral fracture a risk factor for mortality?

Trone DW, Kritz-Silverstein D, von Mühlen DG, Wingard DL, Barrett-Connor E.

Am J Epidemiol. 2007 Nov 15;166(10):1191-7. Epub 2007 Aug 20.

PMID:
17709329
25.
26.

Epidemiology of stress fracture and lower-extremity overuse injury in female recruits.

Rauh MJ, Macera CA, Trone DW, Shaffer RA, Brodine SK.

Med Sci Sports Exerc. 2006 Sep;38(9):1571-7.

PMID:
16960517
27.

Predictors of stress fracture susceptibility in young female recruits.

Shaffer RA, Rauh MJ, Brodine SK, Trone DW, Macera CA.

Am J Sports Med. 2006 Jan;34(1):108-15. Epub 2005 Sep 16.

PMID:
16170040
28.

Running mileage, movement mileage, and fitness in male U.S. Navy recruits.

Trank TV, Ryman DH, Minagawa RY, Trone DW, Shaffer RA.

Med Sci Sports Exerc. 2001 Jun;33(6):1033-8.

PMID:
11404670
29.

Stress fracture in military recruits: gender differences in muscle and bone susceptibility factors.

Beck TJ, Ruff CB, Shaffer RA, Betsinger K, Trone DW, Brodine SK.

Bone. 2000 Sep;27(3):437-44.

PMID:
10962357
30.

Gender differences in musculoskeletal injury rates: a function of symptom reporting?

Almeida SA, Trone DW, Leone DM, Shaffer RA, Patheal SL, Long K.

Med Sci Sports Exerc. 1999 Dec;31(12):1807-12.

PMID:
10613432

Supplemental Content

Support Center